

Bibliografía

1. Lamb Y, Deeks E. Sarilumab: A Review in Moderate to Severe Rheumatoid Arthritis. *Drugs*. 2018;78:929-40.
2. Genovese MC, Fleischmann R, Kivitz AJ, Rell-Bakalarska M, Martincova R, Fiore S, *et al.* Sarilumab Plus Methotrexate in Patients With Active Rheumatoid Arthritis and Inadequate Response to Methotrexate: Results of a Phase III Study. *Arthritis Rheumatol*. 2015;67:1424-37.
3. Fleischmann R, van Adelsberg J, Lin Y, Da Rocha Castelar-Pinheiro G, Brzezicki J, Hrycaj P, *et al.* Sarilumab and Non-Biologic Disease-Modifying Antirheumatic Drugs in Patients With Active RA and Inadequate Response or Intolerance to Tumor Necrosis Factor Inhibitors. *Arthritis Rheumatol*. 2017;69:277-90.
4. Burmester GR, Lin Y, Patel R, van Adelsberg J, Mangan EK, Graham NM, *et al.* Efficacy and safety of sarilumab monotherapy versus adalimumab monotherapy for the treatment of patients with active rheumatoid arthritis (MONARCH): a randomised, double-blind, parallel-group phase III trial. *Ann Rheum Dis*. 2017;76:840-7.
5. Fleischmann R, Genovese M, Lin Y, St John G, van der Heijde D, Wang S, *et al.* Long-term safety of sarilumab in rheumatoid arthritis: an integrated analysis with up to 7 years' follow-up. *Rheumatology (Oxford)*. 2020;59:292-302.
6. Kilcher G, Hummel N, Didden E, Egger M, Reichenbach S. Rheumatoid arthritis patients treated in trial and real world settings: comparison of randomized trials with registries. *Rheumatology*. 2018;57:354-69.
7. Sokka T, Pincus T. Eligibility of patients in routine care for major clinical trials of anti-tumor necrosis factor alpha agents in rheumatoid arthritis. *Arthritis Rheumatism*. 2003;48:313-8.
8. Smolen J, Landewé R, Bijlsma J, Burmester G, Dougados M, Kerschbaumer A, *et al.* EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. *Ann Rheum Dis*. 2020;annrheumdis-2019-216655. [Epub antes de impresión].
9. Takashima S, Ota M. Methotrexate-induced nodulosis. *CMAJ*. 2015;187:E327.
10. Gabay C, Emery P, van Vollenhoven R, Dikranian A, Alten R, Pavelka K, *et al.* Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial. *Lancet*. 2013;381:1541-50.
11. Murota A, Kaneko Y, Yamaoka K, Takeuchi T. Safety of Biologic Agents in Elderly Patients with Rheumatoid Arthritis. *J Rheumatology*. 2016;43:1984-8.